KOSPI slides sharply while select equities post strong rebounds

The KOSPI fell 4.58% to 6,296.38 points, dragged down by heavy foreign outflows of about KRW 3.33 billion, while the KOSDAQ edged up 0.26% to 801.67. The won weakened to 1,428.89 per USD. Institutional buying was modest on the main board but helped the secondary market, setting a mixed tone for the close.

APR (278470) +5.73%

APR surged 5.73% on the back of three converging factors. Analysts noted that the sharp July price drop re‑valued the stock, making its valuation attractive and reviving buying interest [1]. Expectations of strong Q2 earnings and a broader re‑assessment of growth prospects further lifted the share price [4][6]. Finally, the upcoming lock‑up release was mitigated by the CEO’s statement that he has no intention to sell, easing investor concerns [2].

KUMHOTIRECO.,INC (073240) +7.59%

KUMHOTIRECO.,INC jumped 7.59% after market sentiment turned positive on two fronts. First, investors anticipate a recovery in earnings momentum following the fourth‑quarter results, which analysts say could drive the stock higher [8]. Second, a Money Today feature naming the company a "big‑hit" stock for the next session sparked additional buying enthusiasm, amplifying the rally [11]. The combination of earnings optimism and media endorsement propelled the share price sharply higher.

Onconic Therapeutics Inc. (476060) +22.33%

Onconic Therapeutics rocketed 22.33% after securing its first overseas product approval. The company received Indian market clearance for its gastro‑esophageal reflux drug "Zaqubo," opening a potential revenue stream of roughly KRW 1.4 billion, which investors welcomed [15]. Multiple outlets reported the approval simultaneously, creating a broad positive spill‑over that lifted the share price by about 25% in a single day [12][14][16][17]. The confluence of regulatory success and market‑size expectations drove the sharp rally.

CLOBOT Co., Ltd (466100) +10.74%

CLOBOT advanced 10.74% as the Korean government announced a new robot‑industry promotion plan, which singled out CLOBOT and its peer RoboStar for strong upside, lifting both stocks into double‑digit gains [20][21][22][23]. While a separate report highlighted governance concerns—executive sell‑offs and a major shareholder’s non‑participation in a rights issue—the price movement appears to be driven primarily by the policy stimulus rather than the controversy [18]. The policy‑driven optimism dominated market reaction.

InBody Co., Ltd. (041830) +23.46%

InBody surged 23.46% on a confluence of strong fundamentals and buying pressure. Foreign and institutional investors bought simultaneously, pushing the stock up about 19% intraday [24]. The company also reported a 71% year‑on‑year increase in Q2 operating profit to KRW 177 billion, with operating margin improving markedly, reinforcing earnings expectations [25]. Additionally, expanding demand for its body‑composition analyzers contributed to a 70% profit rise, further bolstering investor confidence [26].

Sources

1. 한투證 “에이피알, 7월 주가 급락으로 밸류에이션 매력 높아” - 조선비즈 — Chosunbiz · 2026-08-02
2. 에이피알, 이달말 보호예수 해제…"김병훈 대표 주식 매도 관심 없어" — 연합인포맥스 · 2026-08-05
3. 에이피알 주가, 8월 6일 장중 370,000원 3.50% 상승 — 톱스타뉴스 · 2026-08-06
4. [특징주] 에이피알, 2분기 호실적 기대에 강세⋯“8월엔 주가 반등” — v.daum.net · 2026-08-03
5. "화장품 업종 최선호주" 에이피알, 최대 실적에 주가 상승 — gukjenews.com · 2026-08-06
6. 한국투자증권 "에이피알, 실적과 성장성 재평가.. 반등 가능" — 글로벌이코노믹 · 2026-08-02
7. 금호타이어 주가, 8월 3일 6,660원 8.64% 하락 마감 — 톱스타뉴스 · 2026-08-03
8. 금호타이어 주가 6%↑ "4분기 이후 실적 모멘텀 회복" — gukjenews.com · 2026-08-06
9. 금호타이어 주가, 급등세... 왜? — 금강일보 · 2026-08-06
10. 금호타이어 주가, 8월 5일 장중 7,490원 7.31% 상승 기록 — 톱스타뉴스 · 2026-08-05
11. [적중! 대박 예감] '비에이치아이, 금호타이어' 내일장 예감 좋은 대박 종목은? - 머니투데이 — 머니투데이 · 2026-08-04
12. 온코닉테라퓨틱스, 자큐보 인도 품목허가에 주가 25% 급등 — 한국경제 · 2026-08-06
13. 온코닉테라퓨틱스 주가, 8월 3일 11,240원 3.88% 상승 마감 — 톱스타뉴스 · 2026-08-03
14. 온코닉테라퓨틱스, 인도서 품목허가 획득…25% 급등 — 이코노뉴스 · 2026-08-06
15. 온코닉테라퓨틱스 '자큐보', 인도 품목허가 획득…14억 시장 진출 본격화 - 머니투데이 — 머니투데이 · 2026-08-06
16. 온코닉테라퓨틱스 ‘자큐보’, 인도서 해외 첫 품목허가…현지 출시 채비 — 서울경제 · 2026-08-06
17. 온코닉테라퓨틱스 위식도역류 신약 ‘자큐보’, 인도 품목허가…해외 상업화 첫발 - 조선비즈 — Chosunbiz · 2026-08-06
18. [IB토마토]클로봇, 임원은 고점 매도·최대주주는 유증 외면…책임투자 도마 — 뉴스토마토 · 2026-08-03
19. 클로봇 주가, 급등세... 왜? — 금강일보 · 2026-08-06
20. 정부 로봇산업 육성 발표…클로봇·로보스타 강세 — 이코노뉴스 · 2026-08-06
21. [특징주] 클로봇, 정부 로봇산업 육성 정책에 14%대 강세 — 아이뉴스24 · 2026-08-06
22. [속보] 일부 로봇주 주가 장초반 강세…클로봇·로보스타 두 자릿수 상승률 급등 — CBC뉴스 · 2026-08-06
23. 로봇 관련주, 정부 로봇산업 육성 계획 발표에 줄급등…클로봇 14%대↑ — 매일경제 · 2026-08-06
24. [장중수급포착] 인바디, 외국인/기관 동시 순매수… 주가 +19.22% — 뉴스핌 · 2026-08-06
25. [잠정실적]인바디, 올해 2Q 영업이익 177억원, 전년동기比 71%↑... 영업이익률 대폭 개선 (연결) — 씽크풀 AI · 2026-08-06
26. [공시 Pick] 인바디, 영업이익 70% 증가·체성분측정기 수요 확대에 강세 — 뉴스투데이 · 2026-08-06
27. [속보] 인바디 VI 발동, 주가 급등...실적 어땠나? — CBC뉴스 · 2026-08-06
28. [오늘 이 종목] “셀바스AI·에스피지·지엔씨에너지·인바디… AI·로봇 및 데이터센터 핵심주에 주목” — v.daum.net · 2026-08-04
29. 인바디, 1억여원 규모 자사주 처분... "발행주식 0.01% 수준으로 가치 희석 경미" — 데이터투자 · 2026-08-06

This is market commentary, not investment advice.